SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Multiple Sclerosis
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
1352458507085976v1
14/5/615    most recent
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Sellebjerg, F
Right arrow Articles by Ryder, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sellebjerg, F
Right arrow Articles by Ryder, L.
Right arrowPubmed/NCBI databases
*Substance via MeSH
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

research-article

Gene expression analysis of interferon-β treatment in multiple sclerosis

F Sellebjerg

Department of Neurology, Danish Multiple Sclerosis Research Center, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark, sellebjerg{at}dadlnet.dk

P Datta

Department of Neurology, Danish Multiple Sclerosis Research Center, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark; Department of Neurology, Danish Multiple Sclerosis Research Center, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark

J Larsen

Tissue Typing Laboratory, Department of Clinical Immunology, Danish Multiple Sclerosis Research Center, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark

K Rieneck

Institute of Inflammation Research, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark

I Alsing

Tissue Typing Laboratory, Department of Clinical Immunology, Danish Multiple Sclerosis Research Center, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark

A Oturai

Department of Neurology, Danish Multiple Sclerosis Research Center, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark

A Svejgaard

Tissue Typing Laboratory, Department of Clinical Immunology, Danish Multiple Sclerosis Research Center, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark

P Soelberg Sørensen

Department of Neurology, Danish Multiple Sclerosis Research Center, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark

LP Ryder

Tissue Typing Laboratory, Department of Clinical Immunology, Danish Multiple Sclerosis Research Center, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark

Treatment with interferon-β (IFN-β) induces the expression of hundreds of genes in blood mononuclear cells, and the expression of several genes has been proposed as a marker of the effect of treatment with IFN-β. However, to date no molecules have been identified that are stably induced by treatment with IFN-β. We use DNA microarrays to study gene expression in 10 multiple sclerosis (MS) patients who began de novo treatment with IFN-β. After the first injection of IFN-β, the expression of 74 out of 3428 genes changed at least two-fold and statistically significantly (after Bonferroni correction). In contrast, we observed no persisting effects of IFN-β on gene expression. Among the most strongly induced genes was MXA, which has been used in previous biomarker studies in MS. In addition, the study identified the induction of LGALS9 and TCIR1G, involved in negative regulation of T helper type I immunity and T-cell activation, as novel effects of IFN-β therapy in MS.

Key Words: gene expression profiling • interferon-β • microarray • multiple sclerosis

This version was published on June 1, 2008

Multiple Sclerosis, Vol. 14, No. 5, 615-621 (2008)
DOI: 10.1177/1352458507085976


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
NeurologyHome page
D. Hesse, F. Sellebjerg, and P. S. Sorensen
Absence of MxA induction by interferon {beta} in patients with MS reflects complete loss of bioactivity
Neurology, August 4, 2009; 73(5): 372 - 377.
[Abstract] [Full Text] [PDF]


Home page
Therapeutic Advances in Neurological DisordersHome page
P. Soelberg Sorensen
Review: Neutralizing antibodies against interferon-beta
Therapeutic Advances in Neurological Disorders, September 1, 2008; 1(2): 125 - 141.
[Abstract] [PDF]



Advertisement